Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Dyadic International (DYAI)
NASDAQ:DYAI
Dyadic International (DYAI) Stock Price & Analysis
119 Followers
DYAI Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$1.19 - $2.67
Previous Close$1.41
Volume122.54K
Average Volume (3M)107.79K
Market Cap
$44.44M
Enterprise Value$29.31M
Total Cash (Recent Filing)$12.04M
Total Debt (Recent Filing)$125.44K
Price to Earnings (P/E)―
Beta1.53
Next Earnings
Aug 07, 2024EPS Estimate
-$0.07Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.27
Shares Outstanding29,236,814
10 Day Avg. Volume112,200
30 Day Avg. Volume107,787
Standard Deviation0.20
R-Squared0.06
Alpha-0.00471
Financial Highlights & Ratios
Price to Book (P/B)6.72
Price to Sales (P/S)69.19
Price to Cash Flow (P/CF)-6.60
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue11.71
Enterprise Value/Gross Profit31.76
Enterprise Value/Ebitda-38.42
Forecast
1Y Price Target
$6.00Price Target Upside294.74% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
Dyadic International News
PremiumCompany Announcements
Dyadic International Strikes Major Biotech Deal with Proliant
PremiumCompany Announcements
Dyadic International Secures Lucrative Biotech Licensing Deal
PremiumPress Releases
Dyadic to Attend Industry Events in June
Bulls Say, Bears Say
Bulls Say
Market ExpansionDyadic’s C1 protein production platform technology being used to produce vaccines in Africa could accelerate development of critical therapies in underserved countries.
Revenue PotentialDyadic may realize near-term revenues, as the company’s agreement with Rubic includes an equity stake in Rubic and individual product royalties upon a product’s commercialization.
Strategic PartnershipsRecent collaborations represent important steps in further C1 adoption.
Bears Say
Clinical And Regulatory RiskFailure of clinical trials or stringent regulatory requirements may significantly impede the progress of key drug developments, potentially derailing the company's growth trajectory.
Commercialization StrategyAn untested commercialization strategy poses a substantial risk to the successful market entry and sales performance of the company's products.
Financial PerformanceDyadic's recent financial results showing a net loss could reflect underlying challenges in operational efficiency and profitability, which may concern investors about the company's fiscal health.
---
Ownership Overview
42.08% Insiders
3.52% Mutual Funds
5.78% Other Institutional Investors
48.62% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
DYAI FAQ
What was Dyadic International’s price range in the past 12 months?
Dyadic International lowest stock price was $1.19 and its highest was $2.67 in the past 12 months.
What is Dyadic International’s market cap?
Currently, no data Available
When is Dyadic International’s upcoming earnings report date?
Dyadic International’s upcoming earnings report date is Aug 07, 2024 which is in 11 days.
How were Dyadic International’s earnings last quarter?
Dyadic International released its earnings results on May 14, 2024. The company reported -$0.07 earnings per share for the quarter, missing the consensus estimate of N/A by -$0.07.
Is Dyadic International overvalued?
According to Wall Street analysts Dyadic International’s price is currently Undervalued.
Does Dyadic International pay dividends?
Dyadic International does not currently pay dividends.
What is Dyadic International’s EPS estimate?
Dyadic International’s EPS estimate is -$0.07.
How many shares outstanding does Dyadic International have?
Dyadic International has 29,236,814 shares outstanding.
What happened to Dyadic International’s price movement after its last earnings report?
Dyadic International reported an EPS of -$0.07 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 5.369%.
Which hedge fund is a major shareholder of Dyadic International?
Among the largest hedge funds holding Dyadic International’s share is Bandera Partners. It holds Dyadic International’s shares valued at 3M.
---
Dyadic International Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Negative
20 days / 200 days
Momentum
-22.95%
12-Months-Change
Fundamentals
Return on Equity
-102.46%
Trailing 12-Months
Asset Growth
-1.02%
Trailing 12-Months
Company Description
Dyadic International
Dyadic International, Inc. engages in developing a gene expression platform for producing commercial quantities of industrial enzymes and other proteins. It focuses on further improving and applying its proprietary C1 technology, which is used in the discovery, development, and manufacture of biologic medicines and vaccines. The company was founded by Mark A. Emalfarb in 1979 and is headquartered in Jupiter, FL.
---
DYAI Earnings Call
Q1 2024
0:00 / 0:00
---
DYAI Stock 12 Month Forecast
Average Price Target
$6.00
▲(294.74% Upside)
Technical Analysis
Best Analysts Covering DYAI
1 Year
1 Year Success Rate
0/12 ratings generated profit
1 Year Average Return
-30.48%
reiterated a buy rating 19 days ago
Copying Vernon Bernardino's trades and holding each position for 1 Year would result in 0.00% of your transactions generating a profit, with an average return of -30.48% per trade.
---